Is adolescent pertussis vaccination preferable to natural booster infections?

Expert Review of Clinical Pharmacology

Volumn 4, Issue 6, 2011, Pages 705-711

  Hallander, Hans O ^a   Nilsson, Lennart ^a,b   Gustafsson, Lennart ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adolescent booster; aP vaccines; costeffectiveness; surveillance; transmission

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

AGE; BACTERIAL TRANSMISSION; BOOSTER VACCINATION; BORDETELLA PERTUSSIS; DRUG CHOICE; DRUG COST; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNITY; INCIDENCE; PERTUSSIS; REVIEW; SEROEPIDEMIOLOGY; SWEDEN; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADOLESCENT; AGE FACTORS; ANIMALS; BORDETELLA PERTUSSIS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; VACCINATION;

EID: 80155150293     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.55     Document Type: Review

References (36)

1. Forsyth KD, Wirsing Von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25(14), 2634-2642 (2007). (Pubitemid 46400927)
2. Bisgard KM, Pascual FB, Ehresmann KR et al. Infant pertussis: who was the source? Pediatr. Infect. Dis. J. 23(11), 985-989 (2004). (Pubitemid 40824285)
3. Lavine J, Broutin H, Harvill ET, Bjornstad ON. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine 29(1), 11-16 (2010).
4. Kuehn BM. Panel backs wider pertussis vaccination to curb outbreaks, prevent deaths. JAMA 304(24), 2684-2686 (2010).
5. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS 117(12), 912-922 (2009).
6. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(5 Suppl.), S58-S61 (2005). (Pubitemid 40676539)
7. Carlsson RM, Trollfors B. Control of pertussis - lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 27(42), 5709-5718 (2009).
8. Hallander HO, Ljungman M, Storsaeter J, Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS 117(11), 797-807 (2009).
9. Zepp F, Heininger U, Mertsola J et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11(7), 557-570 (2011).
10. De Greeff SC, Mooi FR, Schellekens JF, De Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J. 27(3), 218-223 (2008).
11. Kandola K, Lea A, White W, Santos M. A comparison of pertussis rates in the Northwest Territories: pre- and postacellular pertussis vaccine introduction in children and adolescents. Can. J. Infect. Dis. Med. Microbiol. 16(5), 271-274 (2005). (Pubitemid 41719718)
12. Skowronski DM, De Serres G, Macdonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. 185(10), 1448-1453 (2002). (Pubitemid 34507967)
13. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22(23-24), 3154-3165 (2004). (Pubitemid 39037219)
14. De Vries R, Kretzschmar M, Schellekens JF et al. Cost-effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS One 5(10), e13392 (2010).
15. Lee GM, Lett S, Schauer S et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin. Infect. Dis. 39(11), 1572-1580 (2004). (Pubitemid 39578527)
16. Jardine A, Conaty SJ, Lowbridge C, Staff M, Vally H. Who gives pertussis to infants? Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic, Sydney, 2009. Commun. Dis. Intell. 34(2), 116-121 (2010).
17. Wendelboe AM, Njamkepo E, Bourillon A et al. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26(4), 293-299 (2007). (Pubitemid 46596651)
18. Preziosi MP, Halloran ME. Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21(17-18), 1853-1861 (2003). (Pubitemid 36428775)
19. Trollfors B, Taranger J, Lagergard T et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr. Infect. Dis. J. 17(3), 196-199 (1998). (Pubitemid 28146059)
20. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 330(6006), 982-985 (2010).
21. Pichichero ME, Detora LM, Johnson DR. An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. Expert Rev. Vaccines 5(2), 175-187 (2006). (Pubitemid 44179949)
22. Hethcote HW, Horby P, Mcintyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22(17-18), 2181-2191 (2004). (Pubitemid 38626056)
23. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin. Infect. Dis. 39(1), 20-28 (2004). (Pubitemid 38879544)
24. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 115(6), 1675-1684 (2005). (Pubitemid 43843179)
25. De Greeff SC, Lugner AK, Van Den Heuvel DM, Mooi FR, De Melker HE. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 27(13), 1932-1937 (2009).
26. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18(2), 326-382 (2005). (Pubitemid 40548297)
27. Van Gent M, De Greeff SC, Van Der Heide HG, Mooi FR. An investigation into the cause of the 1983 whooping cough epidemic in The Netherlands. Vaccine 27(13), 1898-1903 (2009).
28. Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 118(11), 878-887 (2010).
29. Knuf M, Schmitt HJ, Wolter J et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J. Pediatr. 152(5), 655-660, 660.e1 (2008).
30. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin. Infect. Dis. 52(2), 157-162 (2011).
31. Mooi FR, De Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect. Dis. 7(9), 614-624 (2007). (Pubitemid 47268217)
32. Mielcarek N, Debrie AS, Raze D et al. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine 24(Suppl. 2), 54-55 (2006).
33. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev. 1, CD001478 (2011).
34. WHO. Global and regional immunization profile 2010 http://apps.who.int/ immunization-monitoring/en/globalsummary/GS-GLOProfile.pdf?CFID= 4763167&CFTO KEN=89029539
35. Nilsson L, Rydevik G. Twelve year report. Pertussis surveillance in Sweden. SMI Report Series No. 1: 2010 www.smittskyddsinstitutet.se/upload/ Publikationer/smirapport-01-2010.pdf
36. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices 2010 www.ncbi.nlm.nih.gov/entrez/query.fcgi? c md=Retrieve&db=PubMed&dopt=Citatio n&list-uids=2122876